522 related articles for article (PubMed ID: 29051180)
1. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
2. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
4. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
5. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
6. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
7. A concise review of BCL-2 inhibition in acute myeloid leukemia.
Yogarajah M; Stone RM
Expert Rev Hematol; 2018 Feb; 11(2):145-154. PubMed ID: 29264938
[TBL] [Abstract][Full Text] [Related]
8. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
9. ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Naoe T
Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
[TBL] [Abstract][Full Text] [Related]
10. Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G; DiNardo CD
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
[TBL] [Abstract][Full Text] [Related]
11. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
12. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
13. In brief: Two new drugs for AML.
Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
[No Abstract] [Full Text] [Related]
14. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
15. [What is recommended in the treatment of acute myeloid leukemia?].
Thol F
Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
[TBL] [Abstract][Full Text] [Related]
16. First new drug approval for AML in 15 years.
Sheridan C
Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
[No Abstract] [Full Text] [Related]
17. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Gbadamosi M; Meshinchi S; Lamba JK
Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
19. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
20. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
Garitano-Trojaola A; Sancho A; Götz R; Eiring P; Walz S; Jetani H; Gil-Pulido J; Da Via MC; Teufel E; Rhodes N; Haertle L; Arellano-Viera E; Tibes R; Rosenwald A; Rasche L; Hudecek M; Sauer M; Groll J; Einsele H; Kraus S; Kortüm MK
Commun Biol; 2021 Jun; 4(1):799. PubMed ID: 34172833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
